Merck & Company (MRK) 57.69 $MRK
Global Liquid Chromatography Reagents Market 2015-2019 - Product (Column & Planar Chromatography Reagents) & End User (Pharma, Academics, F&B, Hospitals, Cosmetics, Environmental Biotechnology, Nutraceuticals)
M2 - Wed Apr 22, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7rhdw8/liquid) has announced the addition of the "Liquid Chromatography Reagents Market by Product (Column & Planar Chromatography Reagents), by End User (Pharmaceuticals, Academics, Food & Beverages, Hospitals, Cosmetics, Environmental Biotechnology, Nutraceuticals) - Global Forecast to 2019" report to their offering. The global liquid chromatography reagents market is estimated to grow at a CAGR of 11.1% from 2014 to 2019. North America accounted for the largest share of this market, to grow at a CAGR of 9.3% The global liquid chromatography reagents market holds high potential for growth in future, due to increasing strategic expansions of companies and advances in the pharmaceutical and biotechnology industries. However, the high price of organic solvents is the main factor that limits the growth of the market. In this report, the global liquid chromatography reagents market is broadly classified on the basis of products, end-users, and types. Geographically, the market is divided into North America, Europe, Asia, and Rest of World. North America is estimated to command the largest share of 40.3% of the global liquid chromatography reagents market in 2014, followed by Europe. The report has profiled the leading players of this market along with their developments (new product launches & partnerships, agreements, collaborations, and joint ventures) carried out by companies over the past few years and strategies adopted by them to sustain and strengthen their position in the global liquid chromatography reagents market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Global Liquid Chromatography Reagent Market, By Product 6 Global Liquid Chromatography Reagent Market, By Type 7 Global Liquid Chromatography Reagent Market, By End-User 8 Global Liquid Chromatography Reagents Market, By Geography 9 Liquid Chromatography Reagents Market: Competitive Landscape 10 Liquid Chromatography Reagents Market, By Company - Agilent Technologies - Bio-Rad Laboratories, Inc. - GE Healthcare - Merck Millipore - Sigma-Aldrich Corporation - Thermo Fisher Scientific - Waters Corporation For more information visit http://www.researchandmarkets.com/research/7rhdw8/liquid
A: 42.71 (-0.18), SIAL: 138.92 (+0.17), MRK: 57.69 (+0.03), WAT: 124.08 (-0.08)
Organovo inks collaboration deal with Merck; shares up 17% premarket
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 7:50AM CDT
ONVO: 5.14 (+0.67), MRK: 57.69 (+0.03)
Aradigm names Dr Robert A Reed as VP Regulatory (CMC) and Quality
M2 - Wed Apr 22, 7:24AM CDT
Pharmaceutical company Aradigm (NasdaqCM:ARDM) disclosed on Tuesday the appointment of Robert A Reed PhD as vice president of its Regulatory (CMC) and Quality, reporting to its president and chief executive officer Igor Gonda.
MRK: 57.69 (+0.03), ARDM: 6.67 (-0.06), XNPT: 7.42 (+0.12)
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 6.08 (+0.21), ADXS: 22.18 (+0.10), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)
Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal
PR Newswire - Wed Apr 22, 7:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association, today announced that award-winning artist Tim McGraw, who has loved ones impacted by type 2 diabetes, will travel the country to urge people with the disease to get their blood glucose under control. Together, they are launching America's Diabetes Challenge: Get to Your Goals, an educational program that encourages people with type 2 diabetes to work with their doctor to set and reach their A1C, their average blood glucose level over the past 2 to 3 months. Through the program, people living with type 2 diabetes can also learn if they are at risk of low blood glucose, known as hypoglycemia, and how to help reduce that risk. McGraw is challenging people with type 2 diabetes to take the challenge and make a pledge to get to goal with the support of those who care for them.
MRK: 57.69 (+0.03)
Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
PR Newswire - Wed Apr 22, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MRK: 57.69 (+0.03), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), BMY: 66.60 (-0.21)
Exelixis on Path to Beat Estimates; Analyst Brief Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Apr 22, 6:00AM CDT
Exelixis, Inc. (NASDAQ: EXEL) a San Francisco based biotechnology company is set to announce its latest earnings results on April 30, 2015. With recent revisions of earnings estimates, investors are watching to see this darling continue to perform. Exelixis has appreciated significantly since the start of 2015 and growth is expected to continue. Seeing favorable results on its leading compound from the FDA drives the idea of future growth potential.
MRK: 57.69 (+0.03), BMY: 66.60 (-0.21), EXEL: 3.12 (+0.05)
Global Pyrogen Testing Market 2015-2019
M2 - Wed Apr 22, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhh6xx/pyrogen_testing) has announced the addition of the "Pyrogen Testing Market by Product (Instruments, Services, Kits & Reagents), by Test (In Vitro, LAL, Rabbit Test), by Application (Pharmaceutical & Biotechnology Companies, Medical Devices, Other Applications) - Global Forecast to 2019 " report to their offering. Pyrogen testing is used to determine the presence of bacterial toxins in pharmaceutical, biotechnology, and medical device products, which are intended for medical or veterinary use. Spot checks of all batches of pharmaceutical, biotechnology, and medical device products are mandatory for regulatory approval and market release. Pyrogen testing is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the pyrogen testing market. The global pharmaceutical industry is expected to grow at a CAGR between 5% and 8%. According to the IMS Institute of Healthcare Informatics, the global biologics market has increased from $46 billion in 2002 to $169 billion in 2012. Biologics accounted for a share of 11% of the total sales of drugs in 2002, which increased to 18% in 2012. It is estimated that this figure will rise to 20% by 2017, with a total market value of $221 billion. This report segments the pyrogen testing market on the basis of applications, products, tests, and geographies. The application segments included in this report are pharmaceuticals and biologicals, medical devices, and other applications. The product segments of this market are instruments, kits & reagents, and services. The test segments included in this report are in vitro test, LAL test, and rabbit pyrogen test. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Pyrogen Testing Market, By Product 8 Pyrogen Testing Market, By Application 9 Pyrogen Testing Market, By Test 10 Pyrogen Testing Market, By Region 11 Competitive Landscape 12 Company Profiles - Associates of Cape Cod, Inc. - Charles River Laboratories International, Inc. - Ellab A/S - Genscript - Hyglos Gmbh - Lonza Group - Merck & Co., Inc. - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. - Wako Chemicals USA, Inc. For more information visit http://www.researchandmarkets.com/research/zh...en_testing
SIAL: 138.92 (+0.17), MRK: 57.69 (+0.03), CRL: 78.06 (-0.53)
Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:05PM CDT
Bristol-Myers (BMY) announced encouraging results from a phase II study Opdivo in combination with Yervoy.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.04 (+0.02), FOMX: 10.94 (-0.02), PVCT: 0.90 (unch), JNJ: 100.43 (+0.13), DERM: 15.36 (-0.62), ANAC: 66.45 (-0.22), XNCR: 14.63 (-0.16), REGN: 472.63 (+9.41), AQXP: 7.91 (-0.41), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), VRX.TO: 253.14 (-6.24), CBPO: 99.67 (-0.84), MRK: 57.69 (+0.03), CCXI: 7.86 (-0.02), CLTX: 0.74 (-0.01), CELGZ: 2.87 (+0.04), NVS: 103.45 (-0.62)
Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress
Business Wire - Tue Apr 21, 7:30AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. At this year's 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-28 in Copenhagen, Denmark, researchers are scheduled to present more than 30 scientific data presentations on the company's broad portfolio of marketed and investigational anti-infective medicines.
MRK: 57.69 (+0.03)
Aradigm Announces Appointment of Dr. Robert A. Reed as Vice President, Regulatory (Chemistry, Manufacturing and Controls) and Quality
Business Wire - Tue Apr 21, 6:00AM CDT
Aradigm Corporation (NASDAQ:ARDM) ("Aradigm" or the "Company"
today announced that Robert A. Reed, PhD has been appointed as Aradigm's Vice President, Regulatory (CMC) and Quality, reporting to Igor Gonda, President and Chief Executive Officer. Dr. Reed joins Aradigm from Celsion Corporation where he was Senior Vice President of CMC and Technical Operations, overseeing CMC Regulatory and Operations for a liposomal delivery system under clinical development for the treatment of primary liver cancer.
CLSN: 2.92 (+0.03), MRK: 57.69 (+0.03), ARDM: 6.67 (-0.06), XNPT: 7.42 (+0.12)
Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:26PM CDT
Merck (MRK) presented encouraging results at the annual meeting of the American Association for Cancer Research from studies evaluating its anti-PD-1 therapy, Keytruda.
MRK: 57.69 (+0.03), HZNP: 30.96 (+0.10), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)
Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 4:58PM CDT
Bristol-Myers' Study on Opdivo was Halted early as it meets key endpoints.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)
AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing
EP Vantage - at Seeking Alpha - Mon Apr 20, 3:58PM CDT
For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early...
KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals
Steven Giardino - at Seeking Alpha - Mon Apr 20, 12:23PM CDT
GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), MRK: 57.69 (+0.03)
Merck (MRK) Breaks Through Resistance at $57.30
Comtex SmarTrend(R) - Mon Apr 20, 11:51AM CDT
Merck (NYSE:MRK) has opened bullishly above the pivot of $56.94 today and has reached the first level of resistance at $57.30. Investors may be interested in a cross of the next upside pivot targets of $57.73 and $58.52.
MRK: 57.69 (+0.03)
Interesting May Stock Options for MRK
StockOptionsChannel.com - Mon Apr 20, 11:20AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the May...
MRK: 57.69 (+0.03)
Merck files for new indication for Keytruda
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:04AM CDT
MRK: 57.69 (+0.03)
Germany Wealth Report 2015
M2 - Mon Apr 20, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wzl66x/germany_wealth) has announced the addition of the "Germany Wealth Report 2015" report to their offering. The Germany Wealth Report 2014 is an unparalleled resource and the leading resource of its kind. Compiled and curated by a team of expert research specialists, the report comprises a wide variety of data that is created based on over 125,000 HNWIs from around the world in our database. With the wealth reports as the foundation for its research and analysis, this research is able obtain an unsurpassed level of granularity, insight and authority on the HNWI and wealth management universe in each of the countries and regions it covers. The report reviews the performance and asset allocations of HNWIs and ultra-HNWIs. The report also includes projections of the volume, wealth and asset allocations of the HNWIs to 2018 and a comprehensive background of the local economy. The report provides a thorough analysis of the private banking and wealth management sector, the latest merger and acquisition activity, and the opportunities and challenges that it faces. It also provides detailed information on HNWIs volumes in each major city. Key Highlights: - There were 1,356,523 HNWIs in Germany in 2014. These HNWIs held US$4.4 trillion in wealth. - In 2014, German HNWI numbers rose by 2.3%, following the 2013 increase of 4.2%. - Growth in HNWI wealth and volumes are expected to improve over the forecast period. The total number of German HNWIs is forecast to grow by 24.2% to reach 1,745,942 in 2019. HNWI wealth will record a significant percentage increase, growing by 45.6% to reach US$6.6 trillion by 2019. - At the end of 2014, German HNWIs held 34.9% (US$1.5 trillion) of their wealth outside their home country, significantly higher than the worldwide average of 20-30%. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Wealth Sector Fundamentals 4 Findings from the HNWI Database 5 Analysis of German HNWI Investments 6 Competitive Landscape of the Wealth Sector 7 Appendix Companies Mentioned - BHF-Bank Private Banking - Bankhaus Lampe - Bethmann Bank - Commerzbank Private Banking - Deutsche Bank Private Wealth - HSBC Trinkaus - Hypovereinsbank - Merck Finck & Co For more information visit http://www.researchandmarkets.com/research/wz...any_wealth
MRK: 57.69 (+0.03), DB: 33.95 (+0.61)
Global Liquid Chromatography Reagents Market 2015-2019 - Product (Column & Planar Chromatography Reagents) & End User (Pharma, Academics, F&B, Hospitals, Cosmetics, Environmental Biotechnology, Nutraceuticals)
M2 - Wed Apr 22, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7rhdw8/liquid) has announced the addition of the "Liquid Chromatography Reagents Market by Product (Column & Planar Chromatography Reagents), by End User (Pharmaceuticals, Academics, Food & Beverages, Hospitals, Cosmetics, Environmental Biotechnology, Nutraceuticals) - Global Forecast to 2019" report to their offering. The global liquid chromatography reagents market is estimated to grow at a CAGR of 11.1% from 2014 to 2019. North America accounted for the largest share of this market, to grow at a CAGR of 9.3% The global liquid chromatography reagents market holds high potential for growth in future, due to increasing strategic expansions of companies and advances in the pharmaceutical and biotechnology industries. However, the high price of organic solvents is the main factor that limits the growth of the market. In this report, the global liquid chromatography reagents market is broadly classified on the basis of products, end-users, and types. Geographically, the market is divided into North America, Europe, Asia, and Rest of World. North America is estimated to command the largest share of 40.3% of the global liquid chromatography reagents market in 2014, followed by Europe. The report has profiled the leading players of this market along with their developments (new product launches & partnerships, agreements, collaborations, and joint ventures) carried out by companies over the past few years and strategies adopted by them to sustain and strengthen their position in the global liquid chromatography reagents market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Global Liquid Chromatography Reagent Market, By Product 6 Global Liquid Chromatography Reagent Market, By Type 7 Global Liquid Chromatography Reagent Market, By End-User 8 Global Liquid Chromatography Reagents Market, By Geography 9 Liquid Chromatography Reagents Market: Competitive Landscape 10 Liquid Chromatography Reagents Market, By Company - Agilent Technologies - Bio-Rad Laboratories, Inc. - GE Healthcare - Merck Millipore - Sigma-Aldrich Corporation - Thermo Fisher Scientific - Waters Corporation For more information visit http://www.researchandmarkets.com/research/7rhdw8/liquid
A: 42.71 (-0.18), SIAL: 138.92 (+0.17), MRK: 57.69 (+0.03), WAT: 124.08 (-0.08)
Organovo inks collaboration deal with Merck; shares up 17% premarket
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 7:50AM CDT
ONVO: 5.14 (+0.67), MRK: 57.69 (+0.03)
Aradigm names Dr Robert A Reed as VP Regulatory (CMC) and Quality
M2 - Wed Apr 22, 7:24AM CDT
Pharmaceutical company Aradigm (NasdaqCM:ARDM) disclosed on Tuesday the appointment of Robert A Reed PhD as vice president of its Regulatory (CMC) and Quality, reporting to its president and chief executive officer Igor Gonda.
MRK: 57.69 (+0.03), ARDM: 6.67 (-0.06), XNPT: 7.42 (+0.12)
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 6.08 (+0.21), ADXS: 22.18 (+0.10), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)
Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal
PR Newswire - Wed Apr 22, 7:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association, today announced that award-winning artist Tim McGraw, who has loved ones impacted by type 2 diabetes, will travel the country to urge people with the disease to get their blood glucose under control. Together, they are launching America's Diabetes Challenge: Get to Your Goals, an educational program that encourages people with type 2 diabetes to work with their doctor to set and reach their A1C, their average blood glucose level over the past 2 to 3 months. Through the program, people living with type 2 diabetes can also learn if they are at risk of low blood glucose, known as hypoglycemia, and how to help reduce that risk. McGraw is challenging people with type 2 diabetes to take the challenge and make a pledge to get to goal with the support of those who care for them.
MRK: 57.69 (+0.03)
Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
PR Newswire - Wed Apr 22, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MRK: 57.69 (+0.03), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), BMY: 66.60 (-0.21)
Exelixis on Path to Beat Estimates; Analyst Brief Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Apr 22, 6:00AM CDT
Exelixis, Inc. (NASDAQ: EXEL) a San Francisco based biotechnology company is set to announce its latest earnings results on April 30, 2015. With recent revisions of earnings estimates, investors are watching to see this darling continue to perform. Exelixis has appreciated significantly since the start of 2015 and growth is expected to continue. Seeing favorable results on its leading compound from the FDA drives the idea of future growth potential.
MRK: 57.69 (+0.03), BMY: 66.60 (-0.21), EXEL: 3.12 (+0.05)
Global Pyrogen Testing Market 2015-2019
M2 - Wed Apr 22, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhh6xx/pyrogen_testing) has announced the addition of the "Pyrogen Testing Market by Product (Instruments, Services, Kits & Reagents), by Test (In Vitro, LAL, Rabbit Test), by Application (Pharmaceutical & Biotechnology Companies, Medical Devices, Other Applications) - Global Forecast to 2019 " report to their offering. Pyrogen testing is used to determine the presence of bacterial toxins in pharmaceutical, biotechnology, and medical device products, which are intended for medical or veterinary use. Spot checks of all batches of pharmaceutical, biotechnology, and medical device products are mandatory for regulatory approval and market release. Pyrogen testing is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the pyrogen testing market. The global pharmaceutical industry is expected to grow at a CAGR between 5% and 8%. According to the IMS Institute of Healthcare Informatics, the global biologics market has increased from $46 billion in 2002 to $169 billion in 2012. Biologics accounted for a share of 11% of the total sales of drugs in 2002, which increased to 18% in 2012. It is estimated that this figure will rise to 20% by 2017, with a total market value of $221 billion. This report segments the pyrogen testing market on the basis of applications, products, tests, and geographies. The application segments included in this report are pharmaceuticals and biologicals, medical devices, and other applications. The product segments of this market are instruments, kits & reagents, and services. The test segments included in this report are in vitro test, LAL test, and rabbit pyrogen test. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Pyrogen Testing Market, By Product 8 Pyrogen Testing Market, By Application 9 Pyrogen Testing Market, By Test 10 Pyrogen Testing Market, By Region 11 Competitive Landscape 12 Company Profiles - Associates of Cape Cod, Inc. - Charles River Laboratories International, Inc. - Ellab A/S - Genscript - Hyglos Gmbh - Lonza Group - Merck & Co., Inc. - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. - Wako Chemicals USA, Inc. For more information visit http://www.researchandmarkets.com/research/zh...en_testing
SIAL: 138.92 (+0.17), MRK: 57.69 (+0.03), CRL: 78.06 (-0.53)
Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:05PM CDT
Bristol-Myers (BMY) announced encouraging results from a phase II study Opdivo in combination with Yervoy.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.04 (+0.02), FOMX: 10.94 (-0.02), PVCT: 0.90 (unch), JNJ: 100.43 (+0.13), DERM: 15.36 (-0.62), ANAC: 66.45 (-0.22), XNCR: 14.63 (-0.16), REGN: 472.63 (+9.41), AQXP: 7.91 (-0.41), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), VRX.TO: 253.14 (-6.24), CBPO: 99.67 (-0.84), MRK: 57.69 (+0.03), CCXI: 7.86 (-0.02), CLTX: 0.74 (-0.01), CELGZ: 2.87 (+0.04), NVS: 103.45 (-0.62)
Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress
Business Wire - Tue Apr 21, 7:30AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. At this year's 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-28 in Copenhagen, Denmark, researchers are scheduled to present more than 30 scientific data presentations on the company's broad portfolio of marketed and investigational anti-infective medicines.
MRK: 57.69 (+0.03)
Aradigm Announces Appointment of Dr. Robert A. Reed as Vice President, Regulatory (Chemistry, Manufacturing and Controls) and Quality
Business Wire - Tue Apr 21, 6:00AM CDT
Aradigm Corporation (NASDAQ:ARDM) ("Aradigm" or the "Company"
today announced that Robert A. Reed, PhD has been appointed as Aradigm's Vice President, Regulatory (CMC) and Quality, reporting to Igor Gonda, President and Chief Executive Officer. Dr. Reed joins Aradigm from Celsion Corporation where he was Senior Vice President of CMC and Technical Operations, overseeing CMC Regulatory and Operations for a liposomal delivery system under clinical development for the treatment of primary liver cancer. CLSN: 2.92 (+0.03), MRK: 57.69 (+0.03), ARDM: 6.67 (-0.06), XNPT: 7.42 (+0.12)
Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:26PM CDT
Merck (MRK) presented encouraging results at the annual meeting of the American Association for Cancer Research from studies evaluating its anti-PD-1 therapy, Keytruda.
MRK: 57.69 (+0.03), HZNP: 30.96 (+0.10), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)
Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 4:58PM CDT
Bristol-Myers' Study on Opdivo was Halted early as it meets key endpoints.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)
AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing
EP Vantage - at Seeking Alpha - Mon Apr 20, 3:58PM CDT
For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early...
KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals
Steven Giardino - at Seeking Alpha - Mon Apr 20, 12:23PM CDT
GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), MRK: 57.69 (+0.03)
Merck (MRK) Breaks Through Resistance at $57.30
Comtex SmarTrend(R) - Mon Apr 20, 11:51AM CDT
Merck (NYSE:MRK) has opened bullishly above the pivot of $56.94 today and has reached the first level of resistance at $57.30. Investors may be interested in a cross of the next upside pivot targets of $57.73 and $58.52.
MRK: 57.69 (+0.03)
Interesting May Stock Options for MRK
StockOptionsChannel.com - Mon Apr 20, 11:20AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the May...
MRK: 57.69 (+0.03)
Merck files for new indication for Keytruda
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:04AM CDT
MRK: 57.69 (+0.03)
Germany Wealth Report 2015
M2 - Mon Apr 20, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wzl66x/germany_wealth) has announced the addition of the "Germany Wealth Report 2015" report to their offering. The Germany Wealth Report 2014 is an unparalleled resource and the leading resource of its kind. Compiled and curated by a team of expert research specialists, the report comprises a wide variety of data that is created based on over 125,000 HNWIs from around the world in our database. With the wealth reports as the foundation for its research and analysis, this research is able obtain an unsurpassed level of granularity, insight and authority on the HNWI and wealth management universe in each of the countries and regions it covers. The report reviews the performance and asset allocations of HNWIs and ultra-HNWIs. The report also includes projections of the volume, wealth and asset allocations of the HNWIs to 2018 and a comprehensive background of the local economy. The report provides a thorough analysis of the private banking and wealth management sector, the latest merger and acquisition activity, and the opportunities and challenges that it faces. It also provides detailed information on HNWIs volumes in each major city. Key Highlights: - There were 1,356,523 HNWIs in Germany in 2014. These HNWIs held US$4.4 trillion in wealth. - In 2014, German HNWI numbers rose by 2.3%, following the 2013 increase of 4.2%. - Growth in HNWI wealth and volumes are expected to improve over the forecast period. The total number of German HNWIs is forecast to grow by 24.2% to reach 1,745,942 in 2019. HNWI wealth will record a significant percentage increase, growing by 45.6% to reach US$6.6 trillion by 2019. - At the end of 2014, German HNWIs held 34.9% (US$1.5 trillion) of their wealth outside their home country, significantly higher than the worldwide average of 20-30%. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Wealth Sector Fundamentals 4 Findings from the HNWI Database 5 Analysis of German HNWI Investments 6 Competitive Landscape of the Wealth Sector 7 Appendix Companies Mentioned - BHF-Bank Private Banking - Bankhaus Lampe - Bethmann Bank - Commerzbank Private Banking - Deutsche Bank Private Wealth - HSBC Trinkaus - Hypovereinsbank - Merck Finck & Co For more information visit http://www.researchandmarkets.com/research/wz...any_wealth
MRK: 57.69 (+0.03), DB: 33.95 (+0.61)
